Table 4.
Comparison of primary and secondary outcomes between Navigating New Motherhood participants and non-participants in the intervention year
| Bivariable analyses | Multivariable analysis | ||||
|---|---|---|---|---|---|
| Non-participant (N=97) | Participant (N=218) | p-value | aOR (95% CI)* | ||
| Primary outcome | |||||
| Postpartum visit attendance | 61 (62.9) | 192 (88.1) | <0.001 | 4.36 (2.44-7.79) | 5.88 (2.98-11.61) |
| Secondary outcomes | |||||
| WHO Tier 1 or 2 contraception uptake | 50 (51.6) | 161 (73.9) | <0.001 | 2.67 (1.61-4.38) | 2.80 (1.59-4.93) |
| LARC uptake | 25 (25.8) | 88 (40.4) | 0.01 | 1.95 (1.15-3.31) | 2.25 (1.25-4.05) |
| Completion of GTT (if eligible) | 8 (47.1) | 10 (47.6) | 0.97 | 1.02 (0.28-3.68) | 1.30 (0.28-6.03) |
| Received postpartum depression screen | 55 (56.7) | 177 (81.2) | <0.001 | 3.30 (1.95-5.58) | 6.12 (3.18-11.77) |
| Breastfeeding at postpartum visit | 35 (57.4) | 102 (53.4) | 0.59 | 0.85 (0.48-1.52) | 0.72 (0.37-1.38) |
| Received influenza vaccine | 71 (74.0) | 161 (73.9) | 0.98 | 0.99 (0.58-1.72) | 1.08 (0.59-2.00) |
| Received HPV vaccination (if eligible) | 8 (24.2) | 29 (33.3) | 0.28 | 1.92 (0.85-4.33) | 3.70 (1.31-10.46) |
Data displayed as N(%)
aOR, adjusted odds ratio; CI, confidence interval; WHO, World health organization; LARC, long-acting reversible contraception; GTT, glucose tolerance test; HPV, human papillomavirus
*
Controlling for maternal race and ethnicity, primiparity, transfer of care, and diabetes